Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
06/01/20248:00AMBusiness WireMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
06/01/20248:00AMGlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
06/01/20248:00AMGlobeNewswire Inc.CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
06/01/20248:00AMBusiness WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMGlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMBusiness WireAccutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
06/01/20248:00AMGlobeNewswire Inc.OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMGlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:TAKTakeda Pharmaceutical Company Ltd
06/01/20248:00AMGlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
06/01/20247:24AMPR Newswire (Canada)Le loyer étudiant moyen a augmenté de 20% en trois ans à Québec
06/01/20247:10AMPR Newswire (US)Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
06/01/20247:01AMGlobeNewswire Inc.Il documentario Life at the Yellow River Delta vince ai Telly Awards
06/01/20247:00AMGlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
06/01/20247:00AMPR Newswire (Canada)/R A P P E L -- Avis aux médias - Itinéraire du premier ministre pour le samedi 1 juin 2024/
06/01/20247:00AMPR Newswire (Canada)Demain, dimanche 2 juin, le Festival Go vélo Montréal convie les représentants des médias au départ du 39e Tour de l'Île de Montréal !
06/01/20247:00AMPR Newswire (Canada)/R E P R I S E -- Horaire de garde médias du cabinet de la mairesse et du comité exécutif/
06/01/20247:00AMPR Newswire (Canada)/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Saturday, June 1, 2024/
06/01/20246:20AMAlliance NewsAlliance NewsIsrael insists on Hamas "destruction" as part of plan to end Gaza war
06/01/20246:17AMAlliance NewsAlliance NewsPRESS: Ackman's Pershing Square Capital plans IPO, USD1 billion raise
06/01/20245:56AMGlobeNewswire Inc.Aduro Clean Technologies annonce un placement privé d’un montant maximal de 2,5 millions de dollarsTG:9D50Aduro Clean Technologies Inc
06/01/20245:56AMGlobeNewswire Inc.Aduro Clean Technologies kündigt Privatplatzierung von bis zu 2,5 Mio. USD anTG:9D50Aduro Clean Technologies Inc
06/01/20245:55AMPR Newswire (US)ZEEKR Announces May 2024 Delivery UpdateNYSE:ZKZEEKR Intelligent Technology Holding Limited